Key Takeaways

  • Maculaser has secured a new investment from M2care and Zeiss Ventures to accelerate the clinical development and commercialization of its personalized temperature-controlled retinal laser therapy
  • The company’s patented technology enables real-time retinal temperature monitoring during non-damaging laser treatment, aiming to intervene earlier in diseases such as AMD, DME, and CSC
  • M2care and Zeiss Ventures will provide strategic and operational support across clinical development, regulatory planning, manufacturing, and commercialization

Maculaser Oy announced a new undisclosed investment with the participation of M2care, a European healthtech venture studio, and Zeiss Ventures, the corporate venture capital arm of the Zeiss Group. The investment will support Maculaser’s progression toward clinical validation and commercial readiness of its temperature-controlled retinal laser therapy.

Founded in 2020 and rooted in pioneering research at Aalto University, Finland, Maculaser has developed a patented technology that enables real-time, personalized temperature control of the retina during non-damaging laser treatments.

Maculaser’s patented technology introduces a fundamentally different approach to treating retinal conditions: a non-damaging, temperature-controlled retinal laser treatment that activates the natural heat-shock defense mechanisms of retinal cells. By precisely monitoring and controlling retinal temperature in real time during each treatment, Maculaser says the system enables personalized therapy designed to target disease at earlier stages, before irreversible damage occurs.

Backed by M2care and Zeiss Ventures, Maculaser will now begin implementing the clinical development plan for its personalized retinal laser therapy. As part of the investment, M2care will support Maculaser with venture-building expertise across clinical development, regulatory strategy, financing preparation, and commercial planning.

The company said its immediate priority is to advance to first-in-human studies while continuing regulatory and manufacturing workstreams to support clinical validation and future use in ophthalmology clinics.

“This new collaboration marks an important moment for Maculaser,” said Jani Tirronen, CEO and Co-Founder of Maculaser. “With M2care and Zeiss Ventures joining us, we gain not only financial support but also strategic partners who bring deep expertise in healthtech and ophthalmic innovation. Together, we are well positioned to bring temperature-controlled retinal laser therapy to the clinic, where it can make a real difference for millions of patients.”